Seattle Genetics expands ADC pact with Agensys
This article was originally published in Scrip
Executive Summary
Investors were only slightly impressed with Seattle Genetics' new deal with Agensys, an affiliate of Tokyo-based Astellas Pharma, to co-develope a second antibody-drug conjugate (ADC), ASG-22ME (formerly AGS-22M6E).